Clinical trials: Genital Neoplasm, Female
Ovarian Cancer
Primary Debulking Surgery Including Bowel Resection in Advanced Stage Ovarian Cancer Using Caiman® Technology
Longitudinal prospective study on primary debulking surgery including bowel resection in advanced stage ovarian cancer patients using Caiman® technology
- Trial name
- CAIMAN (NCT03219242)
- Testing
- Caiman® device
- Where
- Italy
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Catholic University of the Sacred Heart
Ovarian Cancer
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
This study will evaluate the efficacy and safety of multiple biomarker-selected treatments in patients with persistent or recurrent rare epithelial ovarian, fallopian tube, or primary peritoneal tumors.
- Trial name
- BOUQUET (NCT04931342)
- Testing
- Ipatasertib, Cobimetinib, Trastuzumab Emtansine
- Where
- 41 sites in United States, Australia and 11 more
- Volunteers
- 176 people
- Sponsor
- Hoffmann-La Roche
Cholecystitis, Ovarian Cyst
ONSD According to the Position During Laparoscopy
Increase of intracerebral pressure (ICP) during laparoscopic surgery has known to be associated with positional changes. Optic nerve sheath diameter (ONSD) has correlation with ICP and ultrasonographic measurement of optic nerve…
- Conditions
- Cholecystitis, Ovarian Cyst, Ovarian Cancer, Uterine Myoma
- Trial name
- ONSD (NCT01937104)
- Testing
- Desflurane, Remifentanil, Ultrasonographic measurement of ONSD
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Chosun University Hospital
Cancer Cervix
Vaginal Self-sampling and Human Papillomavirus Testing in Unscreened Women
Despite the existence of an effective screening test (pap smear), cervical cancer is, every year in France, the cause of more than 3,000 new cases and 1,100 deaths.
- Trial name
- APACHE-3 (NCT02255084)
- Testing
- Group 1 remove self sample kit at gp consulting room or perform pap smear, Group 2 perform self sample at home or pap smear
- Where
- France
- Volunteers
- 3,612 people
- Sponsor
- University Hospital, Tours
Epithelial Ovarian Cancer, Renal Cell Carcinoma
HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma
A first-in-human study using HKT288 in solid tumors, including epithelial ovarian cancer and renal cell carcinoma
- Trial name
- NCT02947152
- Testing
- HKT288
- Where
- 6 sites in United States, Australia and 4 more
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals
Endometrial Cancer
A Randomized, Controlled, Comparative Study of a Levonorgestrel Intrauterine System for the Prevention of Endometrial Cancer in Patients Aged 40-50 With BMI Greater Than 35
Endometrial (uterine) cancer affects over 40,000 women each year in the United States. At this time there are no medications to prevent endometrial cancer. Women who are heavy are at increased risk of this cancer.
- Trial name
- NCT00161226
- Testing
- Levonorgestrel intrauterine system
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- University of Medicine and Dentistry of New Jersey
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma
Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase II trial studies the combination of pembrolizumab, bevacizumab, and low dose oral cyclophosphamide in treating patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer.
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma
- Trial name
- NCT02853318
- Testing
- Bevacizumab, Cyclophosphamide, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Roswell Park Cancer Institute
Cervical Intraepithelial Neoplasia Grade 3
Exploratory Study of the Efficacy of HAL-PDT in CIN 3
This is a prospective, multicenter, biomarker-guided Phase II study evaluating the efficacy and safety of hexaminolevulinate-mediated cervical photodynamic therapy (HAL-PDT) in women with cervical intraepithelial neoplasia grade…
- Trial name
- Lumiteg-I (NCT07891338)
- Testing
- Hexaminolevulinate (HAL)
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Tongji Hospital
Cervical Cancer
p16 and Ki-67 Stainings and Natural Killer (NK) Cells in CIN-II Management
The objective of this study is to evaluate the outcome of cervical intraepithelial neoplasia grade 2 (CIN-II) patients followed up without treatment for 24 months according to p16 and ki-67 immunohistochemical staining and to the…
- Trial name
- NCT02522585
- Testing
- Conservative management
- Volunteers
- 100 people
- Sponsor
- Parc de Salut Mar
Recurrent Cervical Cancer, Stage IIIA Cervical Cancer
Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer
This phase II trial studies how well eribulin mesylate works in treating patients with advanced or recurrent cervical cancer. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of…
- Conditions
- Recurrent Cervical Cancer, Stage IIIA Cervical Cancer, Stage IIIB Cervical Cancer, Stage IVA Cervical Cancer
- Trial name
- NCT01676818
- Testing
- eribulin mesylate
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Southern California
Chemotherapy-induced Peripheral Neuropathy, Breast Cancer Metastatic
NR in Chemo-induced Peripheral Neuropathy
The purpose of this single-arm phase II trial is to determine whether nicotinamide riboside (NIAGEN®) prevents the progression of peripheral sensory neuropathy in patients receiving infusions of paclitaxel or nab-paclitaxel for…
- Conditions
- Chemotherapy-induced Peripheral Neuropathy, Breast Cancer Metastatic, Platinum-resistant Recurrent Ovarian Cancer, Head and Neck Cancer Stage IV
- Trial name
- NCT03642990
- Testing
- Nicotinamide Riboside
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Donna Hammond, PhD
Cervical Intraepithelial Neoplasia
Meta-analysis of Efficacy of Topotecan
This meta-analysis was conducted to investigate the efficacy of Topotecan and other treatments for recurrent and stage IVB carcinoma of the cervix
- Trial name
- NCT01160185
- Testing
- paclitaxel, cisplatin, topotecan
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Endometrial Cancer
Study of Insulin Resistance and Endometrial Cancer in Harris County, Texas
The goal of this clinical research study is to find out if there is a link between insulin resistance (or pre-diabetes) and endometrial cancer. Primary Objective: 1.
- Trial name
- NCT00495235
- Testing
- Questionnaire
- Where
- 8 sites in United States
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Cervical Cancer
CervIcal Cancer Screening Trial by Randomization of HPV Testing Intervention for Upcoming Screening （CITRUS Study）
The aim of this study is to assess efficacy of the screening with concurrent liquid-based cytology and HPV DNA testing for the primary cervical cancer screening over 7 years.
- Trial name
- NCT01895517
- Testing
- LBC, LBC plus HPV DNA testing
- Where
- Japan
- Volunteers
- 18,471 people, healthy volunteers welcome
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Endometrial Cancer, Immune Checkpoint Inhibitors
DETERMINANTS OF IMMUNOTHERAPY EFFICACY IN ENDOMETRIAL CANCER
In recent years, the introduction of immune checkpoint inhibitors (ICI) in combination with chemotherapy has significantly changed the management of advanced and recurrent Endometrial Cancer (EC).
- Trial name
- iDEA (NCT07690540)
- Testing
- Prospective exploratory cohort
- Where
- Italy
- Volunteers
- 510 people
- Sponsor
- European Institute of Oncology
Epithelial Ovarian Cancer, Fallopian Tube Cancer
A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
The study is a multicenter, Phase Ib/IIa, open-label, dose-escalation study to evaluate the safety and tolerability of orally administered KAND567 in combination with carboplatin therapy, and to determine the Recommended Phase II…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- KANDOVA (NCT06087289)
- Testing
- KAND567, Carboplatin
- Where
- 4 sites in Denmark, Norway and 1 more
- Volunteers
- 18 people
- Sponsor
- Novakand Pharma AB
Malignancy, Non-hodgkin Lymphoma
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
This clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics (PK) of CYT-0851 in patients with…
- Conditions
- Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer
- Trial name
- NCT03997968
- Testing
- CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine
- Where
- 16 sites in United States
- Volunteers
- 169 people
- Sponsor
- Cyteir Therapeutics, Inc.
Bladder Cancer, Cervical Cancer
Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer
RATIONALE: Radiation therapy can cause long-term adverse effects. Hyperbaric oxygen therapy may be effective in lessening gastrointestinal symptoms caused by radiation therapy given for pelvic cancer.
- Conditions
- Bladder Cancer, Cervical Cancer, Colorectal Cancer, Endometrial Cancer
- Trial name
- NCT01087268
- Testing
- questionnaire administration, gastrointestinal complications management/prevention, quality-of-life assessment
- Where
- United Kingdom
- Volunteers
- 75 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Prostate Cancer, Bladder Cancer
Feasibility Study of Urinary cfDNA Analysis as a Non-invasive Monitoring Tool in Patients With Prostate or Bladder Cancer
The UroDNA study is a feasibility study (RIPH category 3) aimed at evaluating the analysis of circulating tumour DNA in urine (urinary cfDNA) as a non-invasive monitoring tool in patients with prostate or bladder cancer.
- Trial name
- UroDNA (NCT07468838)
- Volunteers
- 25 people
- Sponsor
- Institut Cancerologie de l'Ouest
Endometrial Neoplasms
Endometrial Lesions Predictions
To explore the risk factors of endometrial lesions in patients with abnormal uterine bleeding and establish prediction models which can discriminate between different endometrial etiologies of abnormal uterine bleeding(AUB).
- Trial name
- NCT05588076
- Testing
- no intervention
- Where
- China
- Volunteers
- 900 people
- Sponsor
- Beijing Friendship Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.